ClinicalTrials.gg
CompletedNCT04003155Skylight 1Updated Nov 4, 2024Results posted

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

A Phase 3 interventional study of fezolinetant and placebo in Hot Flashes, sponsored by Astellas Pharma Global Development, Inc.. Completed at 96 sites in 7 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-04.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
527
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.

Enrollment
3rd of 16
527 · median 249
Started
2019
with 2 others
Phase 3
10 of 16
2 open now
Registered
2nd of 16
by date
Lead sponsor
6 of 16
Astellas Pharma Global Development, Inc.

Among the 16 studies testing fezolinetant in Hot Flashes, this one is the 3rd largest by enrollment, is one of 3 that started in 2019, is one of 10 in phase 3, and was the 2nd registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fezolinetant

fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing fezolinetant in Hot Flashes, or all of them as a file.
02

Study summary

This study was for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The study treatments were fezolinetant 30 milligrams (mg) (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo was a dummy treatment that looks like medicine but did not had any medicine in it.) The study compared fezolinetant and placebo after 4 and 12 weeks of dosing. The study evaluated if fezolinetant reduces the number of hot flashes. And the study evaluated if fezolinetant reduces the severity of the hot flashes. Women in the study received an electronic handheld device at the first study visit. (It was similar to a smart phone.) Each day of the study, study participants used this to record their hot flashes. Their record for the 10 days before the start of study treatment was checked. They remained in the study if their record shown 7 or 8 moderate to severe hot flashes per day (50 or more per week). Next, they were picked for 1 of the 2 study treatments (fezolinetant or placebo) by chance alone. It was like flipping a coin. The study participants took study treatment for 52 weeks. The first 12 weeks of study treatment are "double-blinded." That means that the study participants and the study doctors did not knew who took which of the study treatments (fezolinetant 30 mg, fezolinetant 45 mg or placebo) during that time. The last 40 weeks of study treatment are "noncontrolled." That means that each study participant and the study doctors knew which study treatment that study participant took during that time. Women who took fezolinetant during the first 12 weeks continued to take the same dose. Women who took placebo during the first 12 weeks took fezolinetant. Their dose was either 30 mg or 45 mg fezolinetant. At weeks 2, 4, 8, 12, 14, 16 and then once a month, the study participants visited the hospital or clinic for a check-up. They were asked about medications, side effects and how they felt. Other checks included physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine was collected for laboratory tests. Study participants completed questionnaires that were about how hot flashes affect their daily life. Study participants who still had their uterus had the following 2 tests done at the first and last study visits. One of the 2 tests was endometrial biopsy. This test involves removing a small amount of tissue from the inside lining of the uterus. The tissue was then checked under a microscope. The other test is transvaginal ultrasound. This test used sound waves to create pictures of the organs in the pelvis. The sound waves were transmitted by a probe (transducer), which was placed inside the vagina. Study participants may have a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not had this test done in the last 12 months had it done at the first study visit. They had it done at the last study visit if they are due for their screening mammogram and their own doctor agrees. The last check-up at the hospital or clinic was 3 weeks after the last dose of study treatment.

Read the detailed description

This study consisted of a screening period and a 52 week treatment period. Safety follow up occurred 3 weeks after the last dose of study drug.

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • menopause
  • ESN364
  • vasomotor symptoms
  • fezolinetant
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a ≥ 18 kg/m\^2 and ≤ 38 kg/m\^2.
  • Subject must be seeking treatment or relief for vasomotor symptoms (VMS) associated with menopause and confirmed as menopausal per 1 of the following criteria at the screening visit:

    • Spontaneous amenorrhea for ≥ 12 consecutive months
    • Spontaneous amenorrhea for ≥ 6 months with biochemical criteria of menopause (follicle-stimulating hormone [FSH] > 40 IU/L); or
    • Having had bilateral oophorectomy ≥ 6 weeks prior to the screening visit.
  • Within the 10 days prior to randomization, subject must have a minimum average of 7 to 8 moderate to severe hot flashes (HFs) vasomotor symptoms (VMS) per day, or 50 to 60 per week.
  • Subject is in good general health as determined on the basis of medical history and general physical examination, including a bimanual clinical pelvic examination and clinical breast examination devoid of relevant clinical findings, performed at the screening visit; hematology and biochemistry parameters, pulse rate and/or blood pressure and (ECG) within the reference range for the population studied, or showing no deviations.
  • Subject has documentation of a normal/negative or no clinically significant findings mammogram (obtained at screening or within the prior 12 months of study enrollment). Appropriate documentation includes a written report or an electronic report indicating normal/negative or no clinically significant mammographic findings.
  • Subject is willing to undergo a transvaginal ultrasound (TVU) to evaluate the uterus and ovaries at screening and at week 52 end of treatment (EOT), and for subjects who are withdrawn from the study prior to completion, a TVU at the early discontinuation (ED) visit.
  • Subject is willing to undergo an endometrial at screening and at week 52 (EOT), for subjects with uterine bleeding, and for subjects who are withdrawn from the study prior to completion. The endometrial biopsy obtained at screening must be considered evaluable.
  • Subject has documentation of a normal or not clinically significant Papanicolaou (Pap) test (or equivalent cervical cytology) within the previous 12 months or at screening.
  • Subject has a negative urine pregnancy test at screening.
  • Subject has a negative serology panel (i.e., negative surface antigen, negative virus antibody and negative antibody screens) at screening.
  • Subject agrees not to participate in another interventional study while participating in the present study.

Exclusion criteria

Exclusion Criteria:

  • Subject uses a prohibited therapy (strong or moderate cytochrome P450 1A2 [CYP1A2] inhibitors, hormone replacement therapy [HRT], hormonal or any treatment for VMS [prescription, over the counter or herbal]) or is not willing to wash out and discontinue use of such drugs for the full duration of study conduct.
  • Subject has known substance abuse or alcohol addiction within 6 months of screening.
  • Subject has previous or current history of a malignant tumor, except for basal cell carcinoma.
  • Subject's systolic blood pressure is ≥ 130 mmHg or diastolic blood pressure is ≥ 80 mmHg based on the average of 2 to 3 readings, on at least 2 different occasions within the screening period.

    • Subjects who do not meet these criteria may be re-assessed after initiation or review of antihypertensive measures.
    • Subjects with a medical history of hypertension can be enrolled once they are medically clear (stable and compliant).
  • Subject has history of severe allergy, or intolerance to drugs in general, including the study drug and any of its .
  • Subject has an unacceptable result from the TVU assessment at screening (i.e., full length of endometrial cavity cannot be visualized or presence of a finding).
  • Subject has an endometrial confirming presence of disordered proliferative endometrium, endometrial hyperplasia, endometrial cancer or other clinically significant findings at screening.
  • Subject has a history within the last 6 months of undiagnosed uterine bleeding.
  • Subject has a history of seizures or other convulsive disorders.
  • Subject has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine or gynecological disease) or that could confound interpretation of the study outcome.
  • Subject has active liver disease, jaundice or elevated liver aminotransferases ( [ALT] or aspartate aminotransferase [AST]), elevated total or direct , elevated (INR), or elevated alkaline phosphatase (ALP). Patients with mildly elevated ALT or AST up to 1.5 times the (ULN) can be enrolled if total and direct bilirubin are normal. Patients with mildly elevated ALP (up to 1.5 x ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Patients with Gilbert's syndrome with elevated total bilirubin may be enrolled as long as direct bilirubin, and reticulocytes are normal.
  • Subject has creatinine > 1.5 × ULN; or estimated (eGFR) using the Modification of Diet in Renal Disease formula ≤ 59 mL/min per 1.73 m\^2 at screening.
  • Subject has a history of suicide attempt or suicidal behavior within the last 12 months or has suicidal ideation within the last 12 months (a response of "yes" to question 4 or 5 on the suicidal ideation portion of the Columbia Suicide Severity Rating Scale [C-SSRS]), or who is at significant risk to commit suicide at screening and at randomization.
  • Subject has previously been enrolled in a clinical trial with fezolinetant.
  • Subject is participating concurrently in another interventional study or participated in an interventional study within 28 days prior to screening, or received any drug within 28 days or within 5 half-lives prior to screening, whichever is longer.
  • Subject is unable or unwilling to complete the study procedures.
  • Subject has any condition which makes the subject unsuitable for study participation.
  • Subject has had partial or full hysterectomy.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
527 participants (actual)

Study arms

  • Placebo comparator
    Double-blind Period: Placebo

    Participants received fezolinetant matching placebo (two fezolinetant matching placebo tablets) orally, once daily (QD) up to week 12 during double-blind treatment period.

    Drug: placebo

  • Experimental
    Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg

    Participants received fezolinetant 30 mg (one 30 mg fezolinetant tablet and one placebo tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 30 mg orally, QD from week 13 up to Week 52 during extension treatment period.

    Drug: fezolinetant

  • Experimental
    Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg

    Participants received fezolinetant 45 mg (one 30 mg tablet and one 15 mg tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 45 mg orally, QD from week 13 up to Week 52 during extension treatment period.

    Drug: fezolinetant

  • Experimental
    Double-blind Period: Placebo /Extension Period: Fezolinetant 30 mg

    Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 30 mg orally, QD from week 13 up to week 52 during extension treatment period.

    Drug: fezolinetant

  • Experimental
    Double-blind Period: Placebo /Extension Period: Fezolinetant 45 mg

    Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 45 mg orally, QD from week 13 up to week 52 during extension treatment period.

    Drug: fezolinetant

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.

    Time frame: Baseline and week 4

  2. Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.

    Time frame: Baseline and week 12

  3. Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4

    Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.

    Time frame: Baseline and week 4

  4. Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12

    Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.

    Time frame: Baseline and week 12

Secondary outcomes

  1. Change From Baseline in The Mean Patient-reported Outcomes Measurement Information System Sleep Disturbance - Short Form 8b (PROMIS SD SF 8b) Total Score at Week 12

    The PROMIS SD SF 8b assesses self-reported sleep disturbance over the past 7 days and includes perceptions of restless sleep; satisfaction with sleep; refreshing sleep; difficulties sleeping, getting to sleep or staying asleep; amount of sleep; and sleep quality. Because it assesses the participants experience of sleep disturbance, the measure does not focus on specific sleep-disorder symptoms or ask patients to report objective measures of sleep (e.g., total amount of sleep, time to fall asleep and amount of wakefulness during sleep). Responses to each of the 8 items range from 1 (no disturbed sleep) to 5 (disturbed sleep), and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS SD SF 8b indicate more of the disturbed sleep.

    Time frame: Baseline and week 12

  2. Change From Baseline in The Mean Frequency of Moderate, and Severe VMS to Each Study Week Up to Week 12

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.

    Time frame: Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10 and 11

  3. Change From Baseline in The Mean Severity of Moderate, and Severe VMS to Each Study Week Up to Week 12

    Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.

    Time frame: Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10 and 11

  4. Mean Percent Change in The Frequency of Moderate And Severe VMS From Baseline to Each Study Week Up to Week 12

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.

    Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12

  5. Number of Participants With Percent Reduction of >=50% in the Mean Frequency of Moderate and Severe VMS From Baseline to Each Study Week Up to Week 12

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization. Participant has \>=50% reduction from baseline to each post baseline week for the frequency of moderate to severe VMS.

    Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12

  6. Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization. Participant has 100% reduction from baseline to each post baseline week for the frequency of moderate to severe VMS.

    Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12

  7. Number of Participants in Each Category of Patient's Global Impression of Change (PGIC) in VMS at Each Visit

    The PGI is comprised of 2 companion 1-item PRO measures analogous to the Clinical Global Impression (CGI) scales. These measures provide brief, stand-alone global assessments prior to and after initiating a study medication. Patient-perceived change from the initiation of treatment (PGI-C)-VMS is used to evaluate meaningful within-person changes over time in VMS. This measure provides patient-perceived change from the initiation of treatment. The PGI-C VMS asks: "Compared to the beginning of this study, how would you rate your HFs/night sweats now?" Subject ratings range from (1) much better to (7) much worse. Participant ratings range from 1=much better, 2= moderately better, 3= a little better, 4= no change, 5= a little worse, 6= moderately worse, 7= much worse.

    Time frame: Weeks 4, 12, 16, 20, 24, 28, 32, 36, 40, 48, 52 of fezolinetant exposure (weeks 16, 24, 28, 32, 36, 40, 44, 48 and 52 for arms Placebo/Fezolinetant 30 mg and Placebo/Fezolinetant 45 mg)

  8. Change From Baseline in The Mean Frequency of Moderate, and Severe VMS at Week 24

    The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.

    Time frame: Baseline and 24 weeks of fezolinetant exposure (week 36 for arms Placebo/Fezolinetanat 30 mg and Placebo/Fezolinetant 45 mg)

  9. Change From Baseline in The Mean Severity of Moderate, and Severe VMS at Week 24

    Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.

    Time frame: Baseline and 24 weeks of fezolinetant exposure (week 36 for arms Placebo/Fezolinetanat 30 mg and Placebo/Fezolinetant 45 mg)

  10. Number of Participants With Adverse Events

    An AE is any untoward medical occurrence in a participant administered a study drug, \& which does not necessarily have to have a causal relationship with treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with use of a medicinal product (mp) whether or not considered related to the mp. An AE is considered "serious" if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inpatient hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. TEAE was defined as an AE observed from first dose date up to 21 days after last dose.

    Time frame: From first dose date up to 21 days after last dose (to 55 weeks)

07

Results

Posted Aug 12, 2022

Participant flow

Postmenopausal women participants 40 to 65 years of age who had moderate to severe vasomotor symptoms (VMS) and seeking treatment or relief for VMS associated with menopause, confirmed as menopausal, had to have minimum average of 7 to 8 moderate to severe hot flashes (HFs) (VMS) per day within the 10 days prior to randomization and who met the inclusion criteria and none of the exclusion criteria were enrolled in this study.

Double-Blind (DB) Period (12 Weeks)
Participant flow — Double-Blind (DB) Period (12 Weeks)
MilestoneDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 30 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 45 mg
Started17517617600
Full analysis set17517317400
Safety analysis set17517417300
Treated17517317400
Completed15214216100
Not completed23341500
Withdrew: Adverse event98500
Withdrew: Lost to follow-up34000
Withdrew: Protocol violation13300
Withdrew: Withdrawal by subject912400
Withdrew: Miscellaneous17300
Extension Period (EP) (40 Weeks)
Participant flow — Extension Period (EP) (40 Weeks)
MilestoneDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 30 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 45 mg
Started01421587676
Completed01241436267
Not completed01815149
Withdrew: Adverse event05422
Withdrew: Lost to follow-up01311
Withdrew: Withdrawal by subject012795
Withdrew: Miscellaneous00121

Outcome measures

PrimaryChange From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.

Time frame:
Baseline and week 4
Reported as:
Least squares mean · VMS per day
Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4
VMS per dayDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg
Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4-3.32 ± 0.29-5.19 ± 0.30-5.39 ± 0.30
Statistical analysis
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -1.87 · 95% CI -2.69 to -1.05
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.07 · 95% CI -2.89 to -1.25
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Hochberg · p = 0.012
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Hochberg · p = 0.007
PrimaryChange From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · VMS per day
Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12
VMS per dayDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg
Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12-3.90 ± 0.31-6.28 ± 0.32-6.44 ± 0.31
Statistical analysis
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.39 · 95% CI -3.25 to -1.52
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.55 · 95% CI -3.40 to -1.70
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Hochberg · p = 0.012
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Hochberg · p = 0.007
PrimaryChange From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4

Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.

Time frame:
Baseline and week 4
Reported as:
Least squares mean · Score on a scale
Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4
Score on a scaleDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg
Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4-0.27 ± 0.04-0.42 ± 0.04-0.46 ± 0.04
Statistical analysis
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = 0.012 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.15 · 95% CI -0.27 to -0.03
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = 0.002 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.19 · 95% CI -0.30 to -0.07
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Hochberg · p = 0.012
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Hochberg · p = 0.007
PrimaryChange From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12

Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12
Score on a scaleDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg
Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12-0.37 ± 0.05-0.60 ± 0.05-0.57 ± 0.05
Statistical analysis
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = 0.002 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.24 · 95% CI -0.39 to -0.09
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = 0.007 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.20 · 95% CI -0.35 to -0.06
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Hochberg · p = 0.012
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Hochberg · p = 0.007
SecondaryChange From Baseline in The Mean Patient-reported Outcomes Measurement Information System Sleep Disturbance - Short Form 8b (PROMIS SD SF 8b) Total Score at Week 12

The PROMIS SD SF 8b assesses self-reported sleep disturbance over the past 7 days and includes perceptions of restless sleep; satisfaction with sleep; refreshing sleep; difficulties sleeping, getting to sleep or staying asleep; amount of sleep; and sleep quality. Because it assesses the participants experience of sleep disturbance, the measure does not focus on specific sleep-disorder symptoms or ask patients to report objective measures of sleep (e.g., total amount of sleep, time to fall asleep and amount of wakefulness during sleep). Responses to each of the 8 items range from 1 (no disturbed sleep) to 5 (disturbed sleep), and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS SD SF 8b indicate more of the disturbed sleep.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline in The Mean Patient-reported Outcomes Measurement Information System Sleep Disturbance - Short Form 8b (PROMIS SD SF 8b) Total Score at Week 12
Score on a scaleDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg
Change From Baseline in The Mean Patient-reported Outcomes Measurement Information System Sleep Disturbance - Short Form 8b (PROMIS SD SF 8b) Total Score at Week 12-3.2 ± 0.5-3.7 ± 0.6-4.2 ± 0.5
Statistical analysis
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = 0.489 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.5 · 95% CI -2.0 to 1.0
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = 0.155 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -1.1 · 95% CI -2.5 to 0.4
SecondaryChange From Baseline in The Mean Frequency of Moderate, and Severe VMS to Each Study Week Up to Week 12

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.

Time frame:
Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10 and 11
Reported as:
Least squares mean · VMS per day
Change From Baseline in The Mean Frequency of Moderate, and Severe VMS to Each Study Week Up to Week 12
VMS per dayDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg
Week 1-1.82 ± 0.26-3.63 ± 0.26-3.07 ± 0.26
Week 2-2.76 ± 0.28-4.73 ± 0.28-4.58 ± 0.28
Week 3-3.15 ± 0.28-5.14 ± 0.29-5.25 ± 0.29
Week 5-3.49 ± 0.28-5.56 ± 0.29-5.67 ± 0.29
Week 6-3.58 ± 0.29-5.70 ± 0.30-5.97 ± 0.29
Week 7-3.71 ± 0.30-5.80 ± 0.31-5.97 ± 0.30
Week 8-3.71 ± 0.30-6.10 ± 0.31-6.10 ± 0.30
Week 9-4.09 ± 0.30-6.16 ± 0.31-6.24 ± 0.30
Week 10-4.09 ± 0.30-6.30 ± 0.31-6.25 ± 0.30
Week 11-3.89 ± 0.31-6.37 ± 0.31-6.34 ± 0.30
Statistical analysis
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -1.81 · 95% CI -2.53 to -1.09
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -1.25 · 95% CI -1.97 to -0.53
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -1.97 · 95% CI -2.75 to -1.19
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -1.83 · 95% CI -2.60 to -1.05
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -1.99 · 95% CI -2.79 to -1.19
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.10 · 95% CI -2.90 to -1.31
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.07 · 95% CI -2.87 to -1.27
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.18 · 95% CI -2.98 to -1.39
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.11 · 95% CI -2.92 to -1.30
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.39 · 95% CI -3.19 to -1.59
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.10 · 95% CI -2.95 to -1.25
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.27 · 95% CI -3.11 to -1.42
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.39 · 95% CI -3.25 to -1.54
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.39 · 95% CI -3.23 to -1.55
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.08 · 95% CI -2.93 to -1.22
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.16 · 95% CI -3.00 to -1.31
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.21 · 95% CI -3.05 to -1.37
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.16 · 95% CI -2.98 to -1.33
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.48 · 95% CI -3.34 to -1.62
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -2.45 · 95% CI -3.30 to -1.60
SecondaryChange From Baseline in The Mean Severity of Moderate, and Severe VMS to Each Study Week Up to Week 12

Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.

Time frame:
Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10 and 11
Reported as:
Least squares mean · Score on a scale
Change From Baseline in The Mean Severity of Moderate, and Severe VMS to Each Study Week Up to Week 12
Score on a scaleDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg
Week 1-0.15 ± 0.03-0.25 ± 0.03-0.25 ± 0.03
Week 2-0.21 ± 0.03-0.35 ± 0.04-0.36 ± 0.03
Week 3-0.27 ± 0.04-0.43 ± 0.04-0.43 ± 0.04
Week 5-0.29 ± 0.04-0.46 ± 0.04-0.46 ± 0.04
Week 6-0.30 ± 0.05-0.50 ± 0.05-0.55 ± 0.05
Week 7-0.28 ± 0.05-0.52 ± 0.05-0.54 ± 0.05
Week 8-0.29 ± 0.05-0.57 ± 0.05-0.53 ± 0.05
Week 9-0.35 ± 0.05-0.62 ± 0.05-0.56 ± 0.05
Week 10-0.34 ± 0.05-0.62 ± 0.05-0.57 ± 0.05
Week 11-0.37 ± 0.06-0.64 ± 0.06-0.61 ± 0.06
Statistical analysis
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = 0.006 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.10 · 95% CI -0.17 to -0.03
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = 0.006 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.10 · 95% CI -0.17 to -0.03
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = 0.003 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.15 · 95% CI -0.24 to -0.05
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = 0.002 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.15 · 95% CI -0.25 to -0.06
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = 0.004 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.16 · 95% CI -0.27 to -0.05
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = 0.003 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.17 · 95% CI -0.28 to -0.06
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = 0.006 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.17 · 95% CI -0.29 to -0.05
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = 0.004 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.17 · 95% CI -0.29 to -0.06
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = 0.003 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.20 · 95% CI -0.33 to -0.07
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.25 · 95% CI -0.38 to -0.13
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.24 · 95% CI -0.37 to -0.11
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.26 · 95% CI -0.39 to -0.13
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.28 · 95% CI -0.41 to -0.15
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.24 · 95% CI -0.37 to -0.11
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Mmrm: -0.26 · 95% CI -0.41 to -0.12
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = 0.004 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.21 · 95% CI -0.35 to -0.06
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.28 · 95% CI -0.43 to -0.13
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = 0.002 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.23 · 95% CI -0.37 to -0.08
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.27 · 95% CI -0.43 to -0.12
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = 0.002 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -0.24 · 95% CI -0.40 to -0.09
SecondaryMean Percent Change in The Frequency of Moderate And Severe VMS From Baseline to Each Study Week Up to Week 12

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.

Time frame:
Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
Reported as:
Least squares mean · Percent change
Mean Percent Change in The Frequency of Moderate And Severe VMS From Baseline to Each Study Week Up to Week 12
Percent changeDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg
Week 1-16.63 ± 2.31-32.15 ± 2.34-28.84 ± 2.35
Week 2-25.08 ± 2.50-42.37 ± 2.55-43.37 ± 2.54
Week 3-28.81 ± 2.54-46.94 ± 2.59-50.00 ± 2.57
Week 4-30.59 ± 2.67-47.34 ± 2.72-51.65 ± 2.69
Week 5-32.55 ± 2.65-50.12 ± 2.71-54.33 ± 2.67
Week 6-33.35 ± 2.72-51.74 ± 2.78-57.18 ± 2.73
Week 7-34.85 ± 2.86-53.14 ± 2.93-56.26 ± 2.85
Week 8-35.71 ± 2.83-55.88 ± 2.90-56.89 ± 2.83
Week 9-39.64 ± 2.87-56.31 ± 2.93-58.54 ± 2.85
Week 10-39.51 ± 2.81-57.39 ± 2.87-59.01 ± 2.79
Week 11-38.05 ± 2.84-58.37 ± 2.90-60.18 ± 2.82
Week 12-37.06 ± 2.89-57.13 ± 2.95-61.24 ± 2.86
Statistical analysis
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -15.52 · 95% CI -21.99 to -9.06
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -12.22 · 95% CI -18.69 to -5.74
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -17.30 · 95% CI -24.32 to -10.27
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -18.29 · 95% CI -25.30 to -11.29
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -18.13 · 95% CI -25.25 to -11.00
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -21.19 · 95% CI -28.29 to -14.09
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -16.75 · 95% CI -24.24 to -9.26
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -21.05 · 95% CI -28.50 to -13.61
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -17.57 · 95% CI -25.02 to -10.12
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -21.78 · 95% CI -29.18 to -14.39
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -18.39 · 95% CI -26.03 to -10.75
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -23.83 · 95% CI -31.39 to -16.27
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -18.29 · 95% CI -26.33 to -10.25
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -21.41 · 95% CI -29.35 to -13.48
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -20.16 · 95% CI -28.14 to -12.19
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -21.17 · 95% CI -29.04 to -13.30
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -16.67 · 95% CI -24.73 to -8.61
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -18.89 · 95% CI -26.84 to -10.94
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -17.88 · 95% CI -25.77 to -9.99
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -19.50 · 95% CI -27.28 to -11.72
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -20.32 · 95% CI -28.30 to -12.35
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -22.14 · 95% CI -30.00 to -14.28
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -20.08 · 95% CI -28.19 to -11.96
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · MMRM · p = <0.001 (LSM, SE, CI, \& p-values come from MMRM analysis of covariance model with CFB as dv \& trt group, wk \& smoking status as factors, with bl measurement \& bl wt as covariates, as well as an interaction of trt by wk \& interaction of bl measurement by wk.) · Lsmean difference: -24.18 · 95% CI -32.16 to -16.20
SecondaryNumber of Participants With Percent Reduction of >=50% in the Mean Frequency of Moderate and Severe VMS From Baseline to Each Study Week Up to Week 12

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization. Participant has \>=50% reduction from baseline to each post baseline week for the frequency of moderate to severe VMS.

Time frame:
Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
Reported as:
Number · Participants
Number of Participants With Percent Reduction of >=50% in the Mean Frequency of Moderate and Severe VMS From Baseline to Each Study Week Up to Week 12
ParticipantsDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg
Week 1184744
Week 2376475
Week 3426989
Week 4497794
Week 5477694
Week 6507896
Week 7527998
Week 8529387
Week 9568597
Week 104584100
Week 115585100
Week 12527799
Statistical analysis
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.245 · 95% CI 1.823 to 5.999
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.964 · 95% CI 1.658 to 5.497
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.187 · 95% CI 1.363 to 3.549
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.847 · 95% CI 1.786 to 4.601
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.002 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.096 · 95% CI 1.326 to 3.345
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.333 · 95% CI 2.121 to 5.302
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.061 · 95% CI 1.323 to 3.233
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.025 · 95% CI 1.947 to 4.746
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.130 · 95% CI 1.363 to 3.357
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.223 · 95% CI 2.067 to 5.080
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.002 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.049 · 95% CI 1.317 to 3.210
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.097 · 95% CI 1.994 to 4.858
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.002 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 1.984 · 95% CI 1.280 to 3.097
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.062 · 95% CI 1.977 to 4.788
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.748 · 95% CI 1.774 to 4.294
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.379 · 95% CI 1.536 to 3.712
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.051 · 95% CI 1.329 to 3.186
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.701 · 95% CI 1.750 to 4.204
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.725 · 95% CI 1.742 to 4.306
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.921 · 95% CI 2.505 to 6.214
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.104 · 95% CI 1.363 to 3.270
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.953 · 95% CI 1.912 to 4.602
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.005 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 1.894 · 95% CI 1.220 to 2.961
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = <0.001 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.156 · 95% CI 2.035 to 4.944
SecondaryNumber of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization. Participant has 100% reduction from baseline to each post baseline week for the frequency of moderate to severe VMS.

Time frame:
Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
Reported as:
Number · Participants
Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate, and Severe VMS From Baseline to Each Study Week Up to Week 12
ParticipantsDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg
Week 1000
Week 2134
Week 3165
Week 4568
Week 52106
Week 62810
Week 721313
Week 821014
Week 951516
Week 1071718
Week 11101619
Week 1261218
Statistical analysis
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.322 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.158 · 95% CI 0.398 to 64.304
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = 0.225 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.925 · 95% CI 0.569 to 77.353
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.089 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 6.334 · 95% CI 1.064 to 120.422
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = 0.143 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 5.026 · 95% CI 0.797 to 96.916
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.711 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 1.257 · 95% CI 0.370 to 4.468
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = 0.441 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 1.570 · 95% CI 0.508 to 5.328
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.032 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 5.351 · 95% CI 1.383 to 35.172
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = 0.175 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.059 · 95% CI 0.693 to 21.086
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.071 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 4.225 · 95% CI 1.039 to 28.290
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = 0.035 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 5.220 · 95% CI 1.348 to 34.323
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.011 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 7.064 · 95% CI 1.912 to 45.640
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = 0.012 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 6.949 · 95% CI 1.881 to 44.892
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.032 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 5.344 · 95% CI 1.381 to 35.134
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = 0.008 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 7.514 · 95% CI 2.055 to 48.354
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.026 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.238 · 95% CI 1.222 to 10.148
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = 0.019 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.438 · 95% CI 1.311 to 10.714
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.037 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.626 · 95% CI 1.101 to 6.951
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = 0.027 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.758 · 95% CI 1.167 to 7.263
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.210 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 1.690 · 95% CI 0.753 to 3.968
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = 0.087 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.010 · 95% CI 0.923 to 4.634
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 30 mg · Regression, Logistic · p = 0.148 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 2.100 · 95% CI 0.795 to 6.157
  • Double-blind Period: Placebo vs Double-blind Period: Fezolinetant 45 mg · Regression, Logistic · p = 0.015 (Based on logistic regression with treatment group and smoking status (current vs former/never) as factors and mean frequency of vasomotor symptoms at baseline as a covariate.) · Odds ratio (or): 3.262 · 95% CI 1.329 to 9.194
SecondaryNumber of Participants in Each Category of Patient's Global Impression of Change (PGIC) in VMS at Each Visit

The PGI is comprised of 2 companion 1-item PRO measures analogous to the Clinical Global Impression (CGI) scales. These measures provide brief, stand-alone global assessments prior to and after initiating a study medication. Patient-perceived change from the initiation of treatment (PGI-C)-VMS is used to evaluate meaningful within-person changes over time in VMS. This measure provides patient-perceived change from the initiation of treatment. The PGI-C VMS asks: "Compared to the beginning of this study, how would you rate your HFs/night sweats now?" Subject ratings range from (1) much better to (7) much worse. Participant ratings range from 1=much better, 2= moderately better, 3= a little better, 4= no change, 5= a little worse, 6= moderately worse, 7= much worse.

Time frame:
Weeks 4, 12, 16, 20, 24, 28, 32, 36, 40, 48, 52 of fezolinetant exposure (weeks 16, 24, 28, 32, 36, 40, 44, 48 and 52 for arms Placebo/Fezolinetant 30 mg and Placebo/Fezolinetant 45 mg)
Reported as:
Number · Participants
Number of Participants in Each Category of Patient's Global Impression of Change (PGIC) in VMS at Each Visit
ParticipantsDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 30 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 45 mg
Week 4: Much better325072—1
Week 4: Moderately better213324—0
Week 4: A little better444235—0
Week 4: No change552328—0
Week 4: A little worse110—0
Week 4: Moderately worse111—0
Week 4: Much worse600—0
Week 12: Much better3550743144
Week 12: Moderately better2424301416
Week 12: A little better404135168
Week 12: No change37191142
Week 12: A little worse61210
Week 12: Moderately worse41420
Week 12: Much worse30100
Week 16: Much better—120—
Week 16: Moderately better—210—
Week 16: A little better—111—
Week 16: No change—100—
Week 16: A little worse—000—
Week 16: Moderately worse—000—
Week 16: Much worse—000—
Week 20: Much better—11——
Week 20: Moderately better—10——
Week 20: A little better—02——
Week 20: No change—11——
Week 20: A little worse—00——
Week 20: Moderately worse—00——
Week 20: Much worse—00——
Week 24: Much better—5581——
Week 24: Moderately better—2730——
Week 24: A little better—3427——
Week 24: No change—106——
Week 24: A little worse—01——
Week 24: Moderately worse—12——
Week 24: Much worse—01——
Week 28: Much better—01——
Week 28: Moderately better—00——
Week 28: A little better—00——
Week 28: No change—00——
Week 28: A little worse—00——
Week 28: Moderately worse—00——
Week 28: Much worse—00——
Week 32: Much better——0——
Week 32: Moderately better——1——
Week 32: A little better——0——
Week 32: No change——0——
Week 32: A little worse——0——
Week 32: Moderately worse——0——
Week 32: Much worse——0——
Week 36: Much better——00—
Week 36: Moderately better——11—
Week 36: A little better——00—
Week 36: No change——00—
Week 36: A little worse——00—
Week 36: Moderately worse——00—
Week 36: Much worse——00—
Week 40: Much better—0—3339
Week 40: Moderately better—2—812
Week 40: A little better—0—610
Week 40: No change—0—61
Week 40: A little worse—0—21
Week 40: Moderately worse—0—00
Week 40: Much worse—0—00
Week 48: Much better—0———
Week 48: Moderately better—1———
Week 48: A little better—1———
Week 48: No change—0———
Week 48: A little worse—0———
Week 48: Moderately worse—0———
Week 48: Much worse—0———
Week 52: Much better—5671——
Week 52: Moderately better—2630——
Week 52: A little better—2315——
Week 52: No change—68——
Week 52: A little worse—01——
Week 52: Moderately worse—01——
Week 52: Much worse—01——
SecondaryChange From Baseline in The Mean Frequency of Moderate, and Severe VMS at Week 24

The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Baseline was the average number of moderate to severe VMS per 24 hours based on the non-missing values in the 10 days immediately prior to randomization.

Time frame:
Baseline and 24 weeks of fezolinetant exposure (week 36 for arms Placebo/Fezolinetanat 30 mg and Placebo/Fezolinetant 45 mg)
Reported as:
Mean · VMS per day
Change From Baseline in The Mean Frequency of Moderate, and Severe VMS at Week 24
VMS per dayDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 30 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 45 mg
Change From Baseline in The Mean Frequency of Moderate, and Severe VMS at Week 24-7.15 ± 6.02-7.32 ± 4.58-6.89 ± 3.67-7.32 ± 4.53
SecondaryChange From Baseline in The Mean Severity of Moderate, and Severe VMS at Week 24

Severity of moderate to severe VMS per day at post baseline visit was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/Total number of daily mild/moderate/severe hot flashes Moderate VMS was defined as sensation of heat with sweating/dampness, but participant was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.

Time frame:
Baseline and 24 weeks of fezolinetant exposure (week 36 for arms Placebo/Fezolinetanat 30 mg and Placebo/Fezolinetant 45 mg)
Reported as:
Mean · Score on a scale
Change From Baseline in The Mean Severity of Moderate, and Severe VMS at Week 24
Score on a scaleDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 30 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 45 mg
Change From Baseline in The Mean Severity of Moderate, and Severe VMS at Week 24-0.75 ± 0.82-0.77 ± 0.90-0.78 ± 0.80-0.76 ± 0.89
SecondaryNumber of Participants With Adverse Events

An AE is any untoward medical occurrence in a participant administered a study drug, \& which does not necessarily have to have a causal relationship with treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with use of a medicinal product (mp) whether or not considered related to the mp. An AE is considered "serious" if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inpatient hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. TEAE was defined as an AE observed from first dose date up to 21 days after last dose.

Time frame:
From first dose date up to 21 days after last dose (to 55 weeks)
Reported as:
Number · Participants
Number of Participants With Adverse Events
ParticipantsDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 30 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 45 mg
TEAE781081154837
Drug-Related TEAE22202162
Serious TEAE17832
Drug-Related Serious TEAE02000
TEAE Leading to Death00000
Drug-Related TEAE Leading to Death00000
TEAE Leading to Withdrawal of Treatment913821
Drug-Related TEAE Leading to Withdrawal of Treatment77501
Death00000

Adverse events

Collected over From first dose date up to 21 days after last dose (up to 55 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Period: Placebo0/175 (0%)1/175 (0.6%)24/175 (13.7%)
Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg0/174 (0%)7/174 (4%)38/174 (21.8%)
Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg0/173 (0%)8/173 (4.6%)45/173 (26%)
Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg0/76 (0%)3/76 (3.9%)18/76 (23.7%)
Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg0/76 (0%)2/76 (2.6%)14/76 (18.4%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 30 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 45 mg
Foot fractureInjury, poisoning and procedural complications0/1750/1740/1731/760/76
Liver function test increasedInvestigations0/1751/1740/1731/760/76
Apocrine breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1750/1740/1730/761/76
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1750/1740/1731/760/76
Pelvic painReproductive system and breast disorders0/1750/1740/1730/761/76
Chest painGeneral disorders0/1750/1741/1730/760/76
CholelithiasisHepatobiliary disorders1/1750/1741/1730/760/76
COVID-19 pneumoniaInfections and infestations0/1750/1741/1730/760/76
Blood pressure increasedInvestigations0/1750/1741/1730/760/76
Benign lung neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1750/1741/1730/760/76
Most frequent other events
Most frequent other events
EventDouble-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 30 mgDouble-blind Period: Placebo/Extension Period: Fezolinetant 45 mg
HeadacheNervous system disorders13/17511/17414/1733/765/76
COVID-19Infections and infestations0/1759/17411/1734/766/76
Blood alkaline phosphatase increasedInvestigations6/1756/1745/1735/761/76
Alanine aminotransferase increasedInvestigations4/1758/17410/1732/762/76
Blood glucose increasedInvestigations0/17510/1748/1732/760/76
Gamma-glutamyltransferase increasedInvestigations4/1756/1747/1734/760/76
Urinary tract infectionInfections and infestations3/1753/1749/1732/761/76

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(Years)Double-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgTotal
Mean54.7 ± 4.854.1 ± 4.954.3 ± 5.254.4 ± 5.0
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgTotal
Female175176176527
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgTotal
Hispanic or Latino464348137
Not Hispanic or Latino128133128389
Unknown or Not Reported1001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgTotal
Race: White142150143435
Race: Black or African American28212776
Race: American Indian or Alaska Native2013
Race: Asian3339
Race: Pacific Islander0011
Race: More Than One Race0112
Race: Unknown0101
Frequency of Moderate and Severe Vasomotor Symptoms per 24 hours
Frequency of Moderate and Severe Vasomotor Symptoms per 24 hours(VMS per day)Double-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgTotal
Mean10.51 ± 3.7910.65 ± 4.7310.44 ± 3.9210.53 ± 4.16
Severity of Moderate and Severe Vasomotor Symptoms per 24 hours
Severity of Moderate and Severe Vasomotor Symptoms per 24 hours(Score on a scale)Double-blind Period: PlaceboDouble-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mgDouble-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mgTotal
Mean2.43 ± 0.352.39 ± 0.342.40 ± 0.352.41 ± 0.35
08

Study locations

96 sites
  • SEC Clinical Research
    Andalusia, Alabama 36420, United States
  • Central Research Associates
    Birmingham, Alabama 59405, United States
  • Achieve Clinical Research, LLC
    Ensley, Alabama 35218, United States
  • Elite Clinical Studies, LLC
    Phoenix, Arizona 85018, United States
  • Eclipse Clinical Research
    Tucson, Arizona 85745, United States
  • Advanced Clinical Research - Rancho Paseo
    Banning, California 92220, United States
  • Hope Clinical Research, LLC
    Canoga Park, California 91303, United States
  • Alliance Research Inc
    Canoga Park, California 91304, United States
  • Marvel Clinical Research
    Huntington Beach, California 92647, United States
  • Grossmont Center for Clinical Research
    La Mesa, California 91942, United States
  • National Research Institute - Panorama
    Los Angeles, California 90057, United States
  • Northern California Research
    Sacramento, California 95821, United States
  • Precision Research Institute, Inc
    San Diego, California 92114, United States
  • Coastal Connecticut Research, LLC
    New London, Connecticut 06320, United States
  • Emerson Clinical Research Institute
    Washington, District of Columbia 20011, United States
  • Precision Clinical Research
    Coral Springs, Florida 33065, United States
  • American Research Institute, Inc.
    Cutler Bay, Florida 33157, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Universal Axon Clinical Research
    Doral, Florida 33166, United States
  • Fleming Island Center for Clinical Research
    Fleming Island, Florida 32003, United States
  • Clinical Physiology Associates
    Fort Myers, Florida 33912, United States
  • Vital Pharma Research Inc.
    Hialeah, Florida 33016, United States
  • Health Awareness
    Jupiter, Florida 33458, United States
  • GYN Research Center
    Kissimmee, Florida 34741, United States
  • Multi-Specialty Research Associates, Inc.
    Lake City, Florida 32055, United States
  • Altus Research
    Lake Worth, Florida 33461, United States
  • Medical Research Center of Miami II
    Miami, Florida 33134, United States
  • Spotlight research center
    Miami, Florida 33176, United States
  • New Age Medical Research Corporation
    Miami, Florida 33186, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Clinical Neuroscience Solutions, Inc
    Orlando, Florida 32801, United States
  • Clinical Neuroscience Solutions, Inc
    Orlando, Florida 32806, United States
  • Cornerstone Research Institute
    Orlando, Florida 32822, United States
  • St. Johns Center for Clinical Research
    Ponte Vedra, Florida 32081, United States
  • Health Awareness
    Port Saint Lucie, Florida 34952, United States
  • International Clinical Research
    Sanford, Florida 32771, United States
  • Premier Medical Associates
    The Villages, Florida 32159, United States
  • Better Health Greater Life
    Atlanta, Georgia 30312, United States
  • Gwinnett Research Institute
    Buford, Georgia 30519, United States
  • IACT Health
    Columbus, Georgia 31904, United States
  • NuDirections Clinical Research
    Duluth, Georgia 30096, United States
  • Infinite Clinical Trials
    Riverdale, Georgia 30274, United States
  • The Healing Sanctuary, LLC
    Idaho Falls, Idaho 83404, United States
  • Avant Research Associates, LLC
    Crowley, Louisiana 70526, United States
  • Centex Studies, Inc.
    Lake Charles, Louisiana 70601, United States
  • Saginaw Valley Medical Research Group, Llc
    Saginaw, Michigan 48604, United States
  • Montana Medical Research Inc
    Missoula, Montana 59801, United States
  • Quality Clinical Research, Inc
    Omaha, Nebraska 68114, United States
  • Excel Clinical Research, LLC
    Las Vegas, Nevada 89109, United States
  • Office Of Edmond Pack, Md
    Las Vegas, Nevada 89113, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • Unified Women's Clinical Research
    Greensboro, North Carolina 27408, United States
  • Unified Womens Clinical Research
    Raleigh, North Carolina 27607, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • Unified Women's Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Lillestol Research, LLC
    Fargo, North Dakota 58104, United States
  • Velocity Clinical Research
    Cincinnati, Ohio 45242, United States
  • Complete Healthcare For Women
    Columbus, Ohio 43231, United States
  • Neuro-Behavioral Clinical Research, Inc
    North Canton, Ohio 44720, United States
  • Philadelphia Clinical Research, LLC
    Philadelphia, Pennsylvania 19114, United States
  • Ocean State Clinical Research Partners
    Lincoln, Rhode Island 02865, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29406, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Invocare Clinical Research Center
    West Columbia, South Carolina 29169, United States
  • Medical Research Center of Memphis LLC
    Memphis, Tennessee 38120, United States
  • International Clinical Research
    Murfreesboro, Tennessee 37130, United States
  • Accent Clinical Research Professionals
    Allen, Texas 75013, United States
  • DiscoveResarch, Inc.
    Bryan, Texas 77802, United States
  • Protenium Clinical Research, LLC
    Hurst, Texas 76054, United States
  • EPIC Medical Research
    Murray, Utah 84123, United States
  • Tidewater Clinical Research, Inc.
    Virginia Beach, Virginia 23456, United States
  • Site CA15003
    Brampton, Ontario L6T 0G1, Canada
  • Site CA15002
    Point Claire, Quebec H9R 4S3, Canada
  • Site CA15006
    Quebec City, Quebec G3K 2P8, Canada
  • Site CA15001
    Quebec, G1N 4V3, Canada
  • Site CA15004
    Quebec, G1W 4R4, Canada
  • Site CZ42003
    Vodnany, Jihocesky 389 01, Czechia
  • Site CZ42001
    Olomouc, 772 00, Czechia
  • Site HU36004
    Debrecen, 4024, Hungary
  • Site HU36001
    Kecskemet, 6000, Hungary
  • Site HU36002
    Szekesfeherver, 8000, Hungary
  • Site PL48012
    Katowice, Slaskie 40-648, Poland
  • Site PL48003
    Bialystok, 15-224, Poland
  • Site PL48013
    Katowice, 40-301, Poland
  • Site PL48004
    Katowice, 40-611, Poland
  • Site PL48007
    Lublin, 20362, Poland
  • Site PL48005
    Poznan, 60-848, Poland
  • Site PL48014
    Swidnik, 21040, Poland
  • Site PL48009
    Warszawa, 02-679, Poland
  • Site PL48001
    Warszawa, 02-798, Poland
  • Site ES34004
    Sevilla, 41018, Spain
  • Site GB44001
    Wokingham, Berkshire RG40 1XS, United Kingdom
  • Site GB44003
    Orpington, Kent BR5 3QG, United Kingdom
  • Site GB44002
    Coventry, Warwickshire CV3 4FJ, United Kingdom
  • Site GB44004
    Middlesex, HA6 2RN, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Oct 2020, 15 months.

Results were first posted in Aug 2022, 1 year 9 months after primary completion. A results delay was requested in Oct 2021.

Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2019
First posted
Jul 1, 2019
StartActual
Jul 11, 2019
Primary completionActual
Oct 29, 2020
CompletionActual
Aug 11, 2021
Results delay requested
Oct 28, 2021
Results first posted
Aug 12, 2022
Last update
Nov 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04003155
Responsible party
Sponsor
First posted
Jul 1, 2019
Start date
Jul 11, 2019
Primary completion
Oct 29, 2020
Completion
Aug 11, 2021
Results posted
Aug 12, 2022
Last update
Nov 4, 2024

Study contacts

Executive Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion